Skip to main content
Research project

Sean Lim - CELLDEX -RAVE - CRUK (NAC) and Celldex : A phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies (RAVE study).

Staff

Lead researcher

Professor Sean Lim

Professor of Haematology

Research interests

  • Sean Lim's primary research interest is to understand and develop new immunotherapeutic approaches in cancer. Whilst her clinical expertise lies in lymphoid malignancies her laboratory work also involves solid tumours.
  • Monoclonal antibody therapy
  • Her main research programme focuses on understanding the effects of immunostimulatory monoclonal antibodies in cancer, in particular, how they might be combined with direct, tumour targeting antibodies to induce durable anti-tumour responses.  Her work (Turaj et al Cancer Cell 2017) showed that T cells, when activated by an immunostimulatory antibody against CD27, a TNFR superfamily member, led to bystander activation and infiltration of myeloid cells into the tumour microenvironment.  These myeloid cells had enhanced tumour killing capacity when a second tumour-targeting antibody was given in combination. These preclinical observations were translated into a clinical trial (RiVa) for individuals with relapsed B-cell lymphoma (Lim et al, ASH 2021).  More recently, her laboratory has also characterised how a CD27 monoclonal antibody can be engineered to produce improve immunostimulatory capacity (Heckel et al, Communications Biology 2022). Using single-cell technology, her lab is now focusing on understanding how other immunostimulatory antibodies can be used to manipulate adaptive and innate immunity to induce durable anti-cancer responses.
Other researchers

Professor Gareth Griffiths

Director Clinical Trials Unit
Back
to top